Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia

In adults with congenital adrenal hyperplasia, crinecerfont, a corticotropin-releasing factor type 1 receptor antagonist, lowered the mean glucocorticoid dose and decreased the mean androstenedione level.

​   The New England Journal of Medicine: Search Results in Endocrinology